The British Journal of Cancer issued a retraction of a previously published report describing antitumor activity from the recombinant polypeptide GST-NT21MP in breast cancer. The withdrawn findings had proposed CXCR4 pathway inhibition as the mechanism behind the antitumor effect. The journal’s action removes a piece of mechanistic preclinical evidence from the literature base that researchers may have relied on for follow-on experiments or target validation. For drug developers, retractions can prompt pipeline reevaluation when the underlying pathway rationale is no longer supported.